C, experimental design illustrating the time points in which PYGL inhibitor CP-91149 (GPi) and 2DG were added to the groups depicted in D to J. D, representative images of cell invasion through the Boyden chamber from control, 2DG and recovery GBM1 treated with GPi or DMSO. E to G, comparison of the invasive capacity of EV or shG6PC in the presence or absence of GPi.

C, experimental design illustrating the time points in which PYGL inhibitor CP-91149 (GPi) and 2DG were added to the groups depicted in D to J. D, representative images of cell invasion through the Boyden chamber from control, 2DG and recovery GBM1 treated with GPi or DMSO. E to G, comparison of the invasive capacity of EV or shG6PC in the presence or absence of GPi.